{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:32Z","timestamp":1793978852367,"version":"4.8.0"},"reference-count":122,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Invasive fungal infections are associated with high morbidity and mortality, particularly among immunocompromised and critically ill patients. Antifungal therapy is complicated by substantial pharmacokinetic variability, drug\u2013drug interactions, and narrow therapeutic windows for some agents. Although therapeutic drug monitoring (TDM) can optimize drug exposure, therapeutic targets vary across studies and guidelines. The aim of this review was to provide an updated overview of antifungal TDM and support the harmonization of therapeutic ranges based on pharmacokinetic\/pharmacodynamic (PK\/PD) evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive search of major literature databases and international guidelines was conducted through November 2025 to identify studies reporting antifungal therapeutic targets and clinical applications of TDM. When therapeutic ranges differed across studies or guidelines, alternative targets were reported, considering the clinical settings and populations in which they were proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Robust evidence supports routine TDM for triazoles with high pharmacokinetic variability, particularly voriconazole and posaconazole, for which target trough concentrations are well established and associated with clinical outcomes. For isavuconazole, routine TDM is not universally recommended but may benefit selected high-risk populations, including critically ill, pediatric, and obese patients and those receiving extracorporeal therapies. Conversely, routine TDM is not currently recommended for echinocandins or amphotericin B because of limited exposure\u2013response data, although emerging evidence suggests that TDM may be useful in selected clinical scenarios. Variability in PK\/PD targets, analytical methods, and preanalytical factors contributes to inconsistent implementation in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Harmonization of antifungal therapeutic ranges is essential to improve the clinical utility of TDM and support individualized antifungal therapy. Further studies are required to establish standardized targets for all antifungal classes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001539","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:01:07Z","timestamp":1791216067000},"page":"731-741","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Drug Monitoring of Antifungal Agents: Toward Harmonization of Therapeutic Ranges"],"prefix":"10.1097","volume":"48","author":[{"given":"Jessica","family":"Cusato","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Turin, Turin, Italy;"},{"name":"INOC \u2013 Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-1267","authenticated-orcid":false,"given":"Alessia","family":"Cafaro","sequence":"additional","affiliation":[{"name":"Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cairoli","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases and Hepatology, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cangemi","sequence":"additional","affiliation":[{"name":"Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;"},{"name":"Clinical Analysis Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierantonio","family":"Menna","sequence":"additional","affiliation":[{"name":"Department of Science and Bio-Technology, Campus Bio-Medico University, Rome, Italy;"},{"name":"Unit of Clinical Pharmacology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Simeoli","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases and Hepatology, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Tempestilli","sequence":"additional","affiliation":[{"name":"Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Goffredo","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases and Hepatology, Bambino Ges\u00f9 Children's Hospital, IRCCS, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SIBioC Working Group \u201cTherapeutic Drug Monitoring e Personalizzazione della Terapia\u201d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"R1-20261106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2015.10.004","article-title":"The global burden of fungal diseases","volume":"30","author":"Vallabhaneni","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"R2-20261106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations","volume":"31","author":"Pagano","year":"2017","journal-title":"Blood Rev"},{"key":"R3-20261106","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","article-title":"Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study","volume":"49","author":"Koehler","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R4-20261106","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/myc.13130","article-title":"Candidaemia in haematological malignancy patients from a SEIFEM study: epidemiological patterns according to antifungal prophylaxis","volume":"63","author":"Posteraro","year":"2020","journal-title":"Mycoses"},{"key":"R5-20261106","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jof7080588","article-title":"Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach","volume":"7","author":"Bergamasco","year":"2021","journal-title":"J Fungi"},{"key":"R6-20261106","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"key":"R7-20261106","first-page":"347","article-title":"Indications for the harmonization of the therapeutic intervals of antibacterial drugs","volume":"46","author":"Cangemi","year":"2022","journal-title":"Biochim Clin"},{"key":"R8-20261106","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"R9-20261106","first-page":"107","article-title":"Anidulafungina versus fluconazolo: approfondimento clinico sulle linee guida IDSA e ESCMID\/Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines","volume":"22","author":"De Rosa","year":"2014","journal-title":"Infez Med"},{"key":"R10-20261106","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"R11-20261106","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R12-20261106","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R13-20261106","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R14-20261106","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R15-20261106","doi-asserted-by":"crossref","first-page":"ofad468","DOI":"10.1093\/ofid\/ofad468","article-title":"Antifungal therapeutic drug monitoring practices: results of an Emerging Infections Network survey","volume":"10","author":"Benedict","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R16-20261106","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20261106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkm389","article-title":"Antifungal serum concentration monitoring: an update","volume":"61","author":"Goodwin","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R18-20261106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R19-20261106","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R20-20261106","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/cid\/ciu657","article-title":"Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children","volume":"59","author":"Van Der Elst","year":"2014","journal-title":"Clin Infect Dis official Publ Infect Dis Soc America"},{"key":"R21-20261106","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/17512433.2023.2274984","article-title":"The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan","volume":"16","author":"Gatti","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R22-20261106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00474-06","article-title":"Association of fluconazole area under the concentration-time curve\/MIC and dose\/MIC ratios with mortality in nonneutropenic patients with candidemia","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20261106","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect Drug Resist"},{"key":"R24-20261106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13318-017-0445-7","article-title":"A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"43","author":"Wilby","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R25-20261106","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40262-018-0673-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"57","author":"McCarthy","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R26-20261106","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients","volume":"39","author":"Ashkenazi-Hoffnung","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R27-20261106","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"R28-20261106","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R29-20261106","doi-asserted-by":"crossref","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20261106","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R31-20261106","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R32-20261106","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20261106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000494329","article-title":"Isavuconazole: case report and pharmacokinetic considerations","volume":"63","author":"Marchesi","year":"2018","journal-title":"Chemotherapy"},{"key":"R34-20261106","doi-asserted-by":"crossref","first-page":"E469","DOI":"10.1097\/MPH.0000000000001508","article-title":"Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: case report and review of literature","volume":"42","author":"De Leonardis","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"R35-20261106","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"key":"R36-20261106","doi-asserted-by":"crossref","first-page":"e0082923","DOI":"10.1128\/aac.00829-23","article-title":"Isavuconazole use and TDM in real-world pediatric practice","volume":"67","author":"Fern\u00e1ndez Ledesma","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-20261106","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1093\/jac\/dkac196","article-title":"Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation","volume":"77","author":"Kriegl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R38-20261106","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"R39-20261106","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/jac\/dkaa274","article-title":"Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube","volume":"75","author":"McCreary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R40-20261106","doi-asserted-by":"crossref","first-page":"e01643-18","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-20261106","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"R42-20261106","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R43-20261106","doi-asserted-by":"crossref","first-page":"107619","DOI":"10.1016\/j.ijantimicag.2025.107619","article-title":"Therapeutic drug monitoring of isavuconazole: trends and update","volume":"66","author":"Tan","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"R44-20261106","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/INF.0000000000002418","article-title":"Isavuconazole-induced acute liver failure in a pediatric patient with invasive aspergillosis","volume":"38","author":"Brivio","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R45-20261106","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40268-018-0251-y","article-title":"Isavuconazole kinetic exploration for clinical practice","volume":"18","author":"Darnaud","year":"2018","journal-title":"Drugs R D"},{"key":"R46-20261106","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11046-018-0287-0","article-title":"Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature","volume":"184","author":"Pomorska","year":"2019","journal-title":"Mycopathologia"},{"key":"R47-20261106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000547799","article-title":"Role of a therapeutic drug monitoring-guided strategy of isavuconazole for optimizing efficacy\/safety outcomes in onco-hematological pediatric patients: a systematic review","volume":"70","author":"Gatti","year":"2025","journal-title":"Chemotherapy"},{"key":"R48-20261106","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R49-20261106","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mycmed.2018.02.002","article-title":"Isavuconazole: a new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity","volume":"28","author":"Ledoux","year":"2018","journal-title":"J Mycol Med"},{"key":"R50-20261106","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(15)01218-0","article-title":"Isavuconazole: a role for the newest broad-spectrum triazole","volume":"387","author":"Slavin","year":"2016","journal-title":"Lancet"},{"key":"R51-20261106","doi-asserted-by":"crossref","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R52-20261106","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R53-20261106","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QCO.0000000000000740","article-title":"Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions","volume":"34","author":"Lewis","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"R54-20261106","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R55-20261106","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R56-20261106","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R57-20261106","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/17512433.2016.1185361","article-title":"Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis","volume":"9","author":"Kovanda","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R58-20261106","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT)","volume":"26","author":"Stern","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"R59-20261106","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R60-20261106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC\u00ae) guideline for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R61-20261106","doi-asserted-by":"crossref","first-page":"105605","DOI":"10.1016\/j.jsbmb.2020.105605","article-title":"Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals","volume":"199","author":"Beck","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R62-20261106","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0000000000000931","article-title":"Therapeutic drug monitoring of the echinocandin antifungal agents: is there a role in clinical practice? A position statement of the Anti-Infective Drugs Committee of the International Association of therapeutic Drug Monitoring and Clinical Toxicology","volume":"44","author":"Kim","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R63-20261106","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","article-title":"Antifungal drugs TDM: trends and update","volume":"44","author":"Kably","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R64-20261106","doi-asserted-by":"crossref","first-page":"e01545-20","DOI":"10.1128\/AAC.01545-20","article-title":"Impact of loading dose of caspofungin in pharmacokinetic-pharmacodynamic target attainment for severe candidiasis infections in patients in intensive care units: the CASPOLOAD Study","volume":"64","author":"Bailly","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R65-20261106","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R66-20261106","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00277-015-2333-z","article-title":"Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach","volume":"94","author":"Karthaus","year":"2015","journal-title":"Ann Hematol"},{"key":"R67-20261106","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R68-20261106","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.01558-13","article-title":"A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid","volume":"58","author":"Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R69-20261106","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R70-20261106","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R71-20261106","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/jps.22109","article-title":"Review of the basic and clinical pharmacology of sulfobutylether-\u03b2-cyclodextrin (SBECD)","volume":"99","author":"Luke","year":"2010","journal-title":"J Pharm Sci"},{"key":"R72-20261106","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1128\/AAC.01493-15","article-title":"Evaluation of sulfobutylether-\u03b2-cyclodextrin exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration","volume":"59","author":"Morris","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R73-20261106","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R74-20261106","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FTD.0000000000000235","article-title":"Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease","volume":"37","author":"Van Der Elst","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R75-20261106","doi-asserted-by":"crossref","first-page":"1368274","DOI":"10.3389\/fphar.2024.1368274","article-title":"Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"R76-20261106","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1111\/bcp.15495","article-title":"Effects of inflammation on voriconazole levels: a systematic review","volume":"88","author":"Li","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R77-20261106","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R78-20261106","first-page":"511.e1","article-title":"Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a major transplantation center","volume":"28","author":"Lindsay","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"R79-20261106","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R80-20261106","doi-asserted-by":"crossref","first-page":"20420986221127503","DOI":"10.1177\/20420986221127503","article-title":"Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases","volume":"13","author":"Shen","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"R81-20261106","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in Non-asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Ther"},{"key":"R82-20261106","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17425255.2020.1773793","article-title":"Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population","volume":"16","author":"Scott","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R83-20261106","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jiac.2020.11.014","article-title":"Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: a systematic review and meta-analysis","volume":"27","author":"Hanai","year":"2021","journal-title":"J Infect Chemother"},{"key":"R84-20261106","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi"},{"key":"R85-20261106","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2165\/00003495-200363200-00008","article-title":"Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"key":"R86-20261106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","article-title":"Pharmacokinetics and pharmacodynamics of antifungals","volume":"20","author":"Andes","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"R87-20261106","doi-asserted-by":"crossref","first-page":"993330","DOI":"10.3389\/fphar.2022.993330","article-title":"The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: five years of data based on a population pharmacokinetic model and Monte-Carlo simulations","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R88-20261106","doi-asserted-by":"crossref","first-page":"e02466-18","DOI":"10.1128\/AAC.02466-18","article-title":"Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels","volume":"63","author":"Kurland","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R89-20261106","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/jac\/dky189","article-title":"Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis","volume":"73","author":"Gustot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R90-20261106","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","article-title":"Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure","volume":"55","author":"Martial","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R91-20261106","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/FTD.0000000000000874","article-title":"A loading micafungin dose in critically ill patients undergoing continuous venovenous hemofiltration or continuous venovenous hemodiafiltration: a population pharmacokinetic analysis","volume":"43","author":"Garbez","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R92-20261106","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/jphp.13353","article-title":"Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?","volume":"72","author":"Kapralos","year":"2020","journal-title":"J Pharm Pharmacol"},{"key":"R93-20261106","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40262-016-0401-8","article-title":"Does weight impact anidulafungin pharmacokinetics?","volume":"55","author":"Lempers","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R94-20261106","doi-asserted-by":"crossref","first-page":"e00063","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R95-20261106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14656566.2024.2331775","article-title":"An evaluation of rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis","volume":"25","author":"Sharma","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"R96-20261106","doi-asserted-by":"crossref","first-page":"107078","DOI":"10.1016\/j.ijantimicag.2023.107078","article-title":"The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: a systematic review","volume":"63","author":"Jendoubi","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"R97-20261106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mmcr.2012.12.006","article-title":"Insufficient serum caspofungin levels in a paediatric patient on ECMO","volume":"2","author":"Koch","year":"2012","journal-title":"Med Mycol Case Rep"},{"key":"R98-20261106","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-021-01062-6","article-title":"Caspofungin population pharmacokinetic analysis in plasma and peritoneal fluid in septic patients with intra-abdominal infections: a prospective cohort study","volume":"61","author":"Garbez","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R99-20261106","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care"},{"key":"R100-20261106","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","volume":"56","author":"Roger","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R101-20261106","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/1120009X.2020.1737783","article-title":"Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring?","volume":"32","author":"Adembri","year":"2020","journal-title":"J Chemother"},{"key":"R102-20261106","doi-asserted-by":"crossref","first-page":"e01582-16","DOI":"10.1128\/AAC.01582-16","article-title":"Low caspofungin exposure in patients in intensive care units","volume":"61","author":"Van Der Elst","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R103-20261106","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R104-20261106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"R105-20261106","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"R106-20261106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2008.01979.x","article-title":"Amphotericin B lipid preparations: what are the differences?","volume":"14","author":"Adler-Moore","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R107-20261106","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","article-title":"Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections","volume":"69","author":"Moen","year":"2009","journal-title":"Drugs"},{"key":"R108-20261106","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.coph.2007.05.004","article-title":"Pharmacodynamic implications for use of antifungal agents","volume":"7","author":"Lewis","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"R109-20261106","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.44.4.1108-1111.2000","article-title":"Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans","volume":"44","author":"Ernst","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R110-20261106","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/AAC.01030-07","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans","volume":"52","author":"Venisse","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R111-20261106","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/AAC.50.2.469-473.2006","article-title":"Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"50","author":"Wiederhold","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R112-20261106","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R113-20261106","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QCO.0000000000000043","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"R114-20261106","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/biomedicines11071962","article-title":"Biological fluid microsampling for therapeutic drug monitoring: a narrative review","volume":"11","author":"Cafaro","year":"2023","journal-title":"Biomedicines"},{"key":"R115-20261106","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jalm\/jfad139","article-title":"Stability and analytical characterization of voriconazole as measured by immunoassay","volume":"9","author":"Bharti","year":"2024","journal-title":"J Appl Lab Med"},{"key":"R116-20261106","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/00045632211041887","article-title":"Comparison of ultra-performance liquid chromatography and ARK immunoassay for therapeutic drug monitoring of voriconazole","volume":"58","author":"Pe\u00f1a-Lorenzo","year":"2021","journal-title":"Ann Clin Biochem"},{"key":"R117-20261106","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R118-20261106","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40262-023-01274-y","article-title":"Towards model-informed precision dosing of voriconazole: challenging published voriconazole nonlinear mixed-effects models with real-world clinical data","volume":"62","author":"Kluwe","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R119-20261106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40262-024-01361-8","article-title":"Personalized antifungal therapy through model-informed precision dosing of posaconazole","volume":"63","author":"Jansen","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"R120-20261106","doi-asserted-by":"crossref","first-page":"717932","DOI":"10.3389\/fphar.2021.717932","article-title":"Experience of a strategy including CYP2C19 preemptive genotyping followed by therapeutic drug monitoring of voriconazole in patients undergoing allogenic hematopoietic stem cell transplantation","volume":"12","author":"Garc\u00eda-Garc\u00eda","year":"2021","journal-title":"Front Pharmacol"},{"issue":"suppl_1","key":"R121-20261106","doi-asserted-by":"crossref","first-page":"ofae631.1913","DOI":"10.1093\/ofid\/ofae631.1913","article-title":"P-1750. Assessment of antimicrobial stewardship guided CYP2C19 pharmacogenomic voriconazole dosing: practicalities and impact on clinical management","volume":"12","author":"Lindsay","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"R122-20261106","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:00:48Z","timestamp":1793977248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001539","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"2026-03-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}